Calcitonin Gene-related Peptide Receptor (CGPR) Antagonists - Pipeline Insight, 2020

“Calcitonin Gene-related Peptide Receptor (CGPR) Antagonists – Pipeline Insight, 2020,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Calcitonin Gene-related Peptide Receptor (CGPR) Antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Calcitonin Gene-related Peptide Receptor (CGPR) Antagonists Understanding
Calcitonin Gene-related Peptide Receptor (CGPR): Overview
CGRP is a 37-amino acid peptide identified for the first time in 1982, which functions as a potent vasodilator of almost all vascular beds. Specifically, the cranial, mesenteric and coronary arteries have been shown to be densely innervated with CGRP-positive fibers. The relaxant effect of CGRP on smooth muscle cells seems to be more prominent in the distal as compared to the proximal coronary arteries. Most importantly, CGRP is involved in nociceptive transmission in the trigeminal ganglion, the trigeminocervical complex and trigeminothalamic pathway.

Structure and Signaling of the CGRP Receptor
The CGRP receptor is a G protein-coupled receptor formed of three subunits, the receptor activity modifying protein 1 (RAMP1), a single transmembrane protein, the calcitonin-like receptor (CLR), a seven-transmembrane protein and the intracellular receptor component protein (RCP). RAMP and CLR form the cleft for the binding of CGRP and this is the site of action of gepants. RCP is responsible for the intracellular signaling. RAMP1 is also a component of the amylin 1 receptor.

Expression
CGRP receptors are expressed by multiple different cell types within the nervous, cardiovascular, and immune systems that are thought to play important roles in migraine pathology. For example, CGRP receptors have been reported on neurons and glia in the peripheral and central nervous systems, including second order neurons and astrocytes as well as trigeminal ganglion neurons and satellite glial cells. In addition, CGRP receptors are present on meningeal smooth muscle cells and the larger cerebral blood vessels. Another site of CGRP receptors is mast cells found within the dura mater.
Calcitonin Gene-related Peptide Receptor (CGPR) Antagonists
Given the localization of functional CGRP receptors on multiple diverse cell types implicated in the underlying pathology of migraine, the beneficial effects of CGRP receptor antagonists in the acute treatment of migraine likely involves repressing the function of cells located in peripheral tissues as well as in the CNS. Based on preclinical data, blocking CGRP receptor activation would be expected to affect the function of vascular smooth muscle cells, mast cells, trigeminal ganglion neurons, glial cells, and second-order neurons within the CNS.

Calcitonin Gene-related Peptide Receptor (CGPR) Antagonists Emerging Drugs Chapters
This segment of the Calcitonin Gene-related Peptide Receptor (CGPR) Antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Calcitonin Gene-related Peptide Receptor (CGPR) Antagonists Emerging Drugs
• Zavegepant (BHV-3500): Biohaven Pharmaceutical

Zavegepant (BHV-3500) is a third generation, high affinity, selective and structurally unique, small molecule CGRP receptor antagonist. It is also structurally distinct from rimegepant. The chemical properties of zavegepant make the product candidate potentially suitable for multiple routes of delivery, including nasal, subcutaneous, inhalation or oral administration.

• Aimovig (erenumab): Amgen Inc.

Aimovig (erenumab) is an injectable human monoclonal antibody (mAb) co-developed by pharmaceutical companies Novartis and Amgen. Formerly known as AMG 334, Aimovig belongs to a class of drugs known as selective calcitonin gene-related peptide (CGRP) antagonists, used for the treatment of acute migraine attacks.

• Galcanezumab: Eli Lilly and Company

Galcanezumab is a humanized monoclonal antibody against the calcitonin gene-related peptide (CGRP) ligand. A potent vasodilator, CGRP is implicated in nociceptive transmission and migraine pathogenesis. In September 2018, the US FDA approved galcanezumab as a once-monthly subcutaneous injection for the preventive treatment of migraine in adults. In the same month, the EMA issued a positive opinion for galcanezumab for the prophylaxis of migraine in adults who have at least 4 migraine days per month.

Further product details are provided in the report
Calcitonin Gene-related Peptide Receptor (CGPR) Antagonists: Therapeutic Assessment

This segment of the report provides insights about the different Calcitonin Gene-related Peptide Receptor (CGPR) Antagonists drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Calcitonin Gene-related Peptide Receptor (CGPR) Antagonists
• There are approx. 10+ key companies which are developing the therapies for Calcitonin Gene-related Peptide Receptor (CGPR) Antagonists. The companies which have their Calcitonin Gene-related Peptide Receptor (CGPR) Antagonists drug candidates in the most advanced stage, i.e. phase III include, Biohaven Pharmaceuticals, Inc., Novartis etc.
• Phases

The report covers around 10+ products under different phases of clinical development like

• Late-stage products (Phase II and Phase II/III)
• Mid-stage products (Phase II and Phase II/III)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Calcitonin Gene-related Peptide Receptor (CGPR) Antagonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Oral
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal antibodies
• Small molecules
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Calcitonin Gene-related Peptide Receptor (CGPR) Antagonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Calcitonin Gene-related Peptide Receptor (CGPR) Antagonists therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Calcitonin Gene-related Peptide Receptor (CGPR) Antagonists drugs.


Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Calcitonin Gene-related Peptide Receptor (CGPR) Antagonists R&D. The therapies under development are focused on novel approaches to treat/improve Calcitonin Gene-related Peptide Receptor (CGPR) Antagonists.
In August 2020, Biohaven Pharmaceutical announced that it will receive up to $250 million from Royalty Pharma on closing of a deal to fund development of its zavegepant (formerly vazegepant) calcitonin gene-related peptide (CGRP) receptor antagonist program, which includes intranasal zavegepant. The funding also will support the launch of Biohaven’s Nurtec rimegepant for the treatment of migraine. Biohaven will receive $150 million on closing and an additional $100 when it begins the Phase 3 program for its oral formulation of zavegepant.
In August 2020, Biohaven Pharmaceutical has announced that it met with the FDA following completion of Phase 2 clinical trials of its intranasal vazegepant (BHV-3500) for the treatment of migraine and is ready to advance the 10 mg dose of the nasal spray into a Phase 3 trial.

Calcitonin Gene-related Peptide Receptor (CGPR) Antagonists Report Insights

• Calcitonin Gene-related Peptide Receptor (CGPR) Antagonists Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Calcitonin Gene-related Peptide Receptor (CGPR) Antagonists Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Calcitonin Gene-related Peptide Receptor (CGPR) Antagonists drugs?
• How many Calcitonin Gene-related Peptide Receptor (CGPR) Antagonists drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Calcitonin Gene-related Peptide Receptor (CGPR) Antagonists?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Calcitonin Gene-related Peptide Receptor (CGPR) Antagonists therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Calcitonin Gene-related Peptide Receptor (CGPR) Antagonists and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Biohaven Pharmaceuticals, Inc.
• Eli Lilly and Company
• Amgen

Key Products

• Zavegepant
• Galcanezumab
• Erenumab